lisdexamfetamine / Generic mfg. - LARVOL DELTA

Pattern of medication dispensations for attention-deficit/hyperactivity disorder in Manitoba children, adolescents and young: a population-wide retrospective study. (PubMed, BMJ Open) - "Stimulant and non-stimulant dispensations for ADHD increased from 2015 to 2023, consistent with international findings. The increase was observed to be the greatest in the population 19 to 24 years of age and females. While there was a significant increase in most ADHD medications, there was a pronounced increase in lisdexamphetamine and guanfacine, specifically."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

Brazilian Psychiatric Association Guidelines for the Treatment of Eating Disorders. (PubMed, Braz J Psychiatry) - "BN is typically managed in an outpatient setting, focusing on structured nutritional care and CBT-based treatment, with pharmacotherapy adjunctive, preferably fluoxetine. BED is treated in an outpatient setting with structured care and CBT, with lisdexamfetamine as the preferred pharmacotherapy when needed. These guidelines represent a significant advancement in managing eating disorders in Brazil, providing a structured framework for clinical care while also supporting the development of future public mental health policies."

Journal • Anorexia • Binge Eating Disorder • Bulimia • CNS Disorders • Psychiatry

SPONTANEOUS CORONARY ARTERY DISSCETION IN A 26-YEAR-OLD FEMALE RECEIVING LISDEXAMFETAMINE FOR ADHD (CHEST 2026) - No abstract available

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Coronary Artery Disease • Psychiatry

Time Trends in Maternal Attention-Deficit/Hyperactivity Disorder and Medication Use in Pregnancy. (PubMed, J Clin Psychiatry) - "Stimulant medication use (amphetamine, dextroamphetamine, lisdexamfetamine, methylphenidate) was assessed via prescription fills in the year before pregnancy, during pregnancy, and stratified by trimester. Approximately 75% of those prescribed a stimulant in the year prior to conception discontinued it prior to, or in, the first trimester of pregnancy, with stable time trends. The 4-fold increase in maternal ADHD in pregnancy over a 20-year period and 2-fold increase in the use of stimulant medication before and during pregnancy in this group underline the need for clinical guidance on managing ADHD in pregnancy."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Obstetrics • Psychiatry

Updates in treatment strategies in ADHD (WFSBP 2026) - "Lisdexamfetamine, a prodrug cleaved gradually by red blood cell enzymes, provides smoother pharmacokinetics and lower abuse potential due to slower peak concentrations...OROS-methylphenidate mimics twice-daily dosing through osmotic release, while transdermal methylphenidate bypasses first-pass metabolism and reduces appetite suppression. Serdexmethylphenidate and ion-exchange amphetamine preparations further improve duration and plasma stability...These mechanisms may improve emotional dysregulation and provide faster onset than atomoxetine...Investigational therapies include centanafadine, a triple DAT-NET-SERT inhibitor targeting emotional dysregulation; TAAR-1 agonists, which modulate dopamine and glutamate signaling; and metadoxine extended release, which restores GABA-glutamate balance and may preferentially benefit inattentive ADHD...DAT1 and SERT polymorphisms may predict stimulant or serotonergic treatment response, while COMT Val158Met variants influence..."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Psychiatry • Tic Disorders • Tourette Syndrome • COMT

Comparative potential for generating spontaneous signals for abuse and dependence among drugs used for attention deficit hyperactivity disorder: A disproportionality analysis in VigiBase®. (PubMed, Gen Psychiatr) - "Methylphenidate and lisdexamfetamine emerged as the two drugs with the highest likelihood of safety reports related to abuse and dependence. These findings challenge previous statements suggesting that the abuse potential of lisdexamfetamine was lower than that of other psychostimulant drugs used for ADHD and advocate for further pharmacoepidemiological studies in this field."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

AGUALIS: Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents (clinicaltrials.gov) - P=N/A | N=25 | Completed | Sponsor: King's College London | Active, not recruiting ➔ Completed

Trial completion • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Assessing the Concurrent Validity of the Australian Treatment Outcomes Profile in a Methamphetamine Dependent Treatment-Seeking Population. (PubMed, Drug Alcohol Rev) - "The ATOP is valid for use in a treatment-seeking methamphetamine-dependent population, expanding the range of tools for assessment and standardised outcome monitoring across different settings and services."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Mood Disorders • Psychiatry

Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) (clinicaltrials.gov) - P2/3 | N=16 | Completed | Sponsor: Yale University | Active, not recruiting ➔ Completed | N=60 ➔ 16 | Trial completion date: May 2027 ➔ Jun 2026 | Trial primary completion date: May 2027 ➔ Jun 2026

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Factors associated with stimulant persistence among children with ADHD: a retrospective cohort study. (PubMed, Front Pharmacol) - "Lisdexamfetamine was associated with the highest odds of treatment persistence when used as the initial stimulant, compared with the reference group (OR = 2.2, CI = 1.86-2.59), although this finding was based on a relatively small sample (n = 654). In this retrospective cohort study of pediatric patients with ADHD, male sex, low socioeconomic status, early treatment initiation, and first-line lisdexamfetamine were associated with higher persistence."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

The increasing use of cognitive enhancing drugs by those with ADHD and neurotypical individuals: Societal demands, lifestyle preferences, and ethical issues. (PubMed, J Psychopharmacol) - "Stimulant medications such as methylphenidate and lisdexamfetamine effectively improve 'cold' cognitive functions and change dysfuntional neural circuitry to a more typically developing pattern, though emotional dysregulation may persist. In neurotypical individuals, drugs such as methylphenidate and modafinil produce small-to-moderate improvements in cognition, particularly by increasing cognitive effort and motivation, with greatest benefits in those operating below optimal levels. However, their growing use raises ethical concerns regarding safety, fairness, coercion, and regulation. We argue that careful risk-benefit evaluation, long-term research studies, and informed policy are urgently needed to guide responsible use."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Prevalence of Psychostimulant Drug Use Among Medical Students and Specialty Residents in Chilean Universitie. (PubMed, Rev Med Chil) - "The use of psychostimulants among medical students raises ethical and public health concerns, considering the risks of dependency, adverse effects, and academic inequalities. The consumption of psychostimulants is high among medical students and residents in Chile, particularly in advanced stages of training. It highlights the need for ethical and educational interventions in the academic environment."

Journal

Pooled analysis assessing the efficacy and safety of amphetamine derivative adjunctive therapy for bipolar depression. (PubMed, J Affect Disord) - "In this pooled controlled analysis, 8-week adjunctive amphetamine was associated with reduction in depressive symptoms in carefully selected patients with bipolar depression, with no increased risk of treatment-emergent mania/hypomania. Further studies are encouraged to identify clinical correlates of treatment response guiding clinicians when to consider this potentially effective treatment."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Vyvanse in Children Aged 6 to 12 Years (clinicaltrials.gov) - P1 | N=44 | Completed | Sponsor: University of Minnesota | Active, not recruiting ➔ Completed | Trial completion date: Jul 2027 ➔ Jun 2026

Trial completion • Trial completion date • Genetic Disorders • Obesity

Prenatal Acetaminophen (Paracetamol) Use and the Risk of Autism and/or Attention-Deficit/Hyperactivity Disorder Among Sibling-Matched Cohorts. (PubMed, JAMA Intern Med) - "Incident diagnoses per the International Classification of Diseases, Ninth Revision, Clinical Modification, for ASD (code 299) or for ADHD (code 314) or a prescription for ADHD-specific medication licensed in Hong Kong (methylphenidate, atomoxetine, or lisdexamfetamine [BNF, section 4.4]). The positive signals observed in conventional studies are likely attributable to residual familial confounding. These findings provide important reassurance regarding the safety of indicated paracetamol use during pregnancy."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Pain • Psychiatry

Tirzepatide Response in A Patient with Chung-Jansen Syndrome and Coexisting MC4R and VPS13B Mutations (ENDO 2026) - "Interventions prior to his genetic diagnosis included stimulants (Vyvanse), SSRIs, atypical antipsychotics, topiramate, structured residential programs, and transcranial magnetic stimulation, all without meaningful or sustained benefit...At 31 y/o 2.5 mg weekly tirzepatide was started, slowly titrated to 7.5 mg weekly, with concurrent metformin, CPAP treatment and lifestyle changes... This case highlights a novel PHIP pathogenic variant causing Chung-Jansen syndrome, compounded by inherited MC4R and VPS13B mutations, resulting in extreme early-onset obesity with neurodevelopmental implications and severe hyperphagia. Tirzepatide treatment has been well tolerated and associated with a significant reduction in adiposity in this patient. Further follow-up will clarify its long-term weight trajectory."

Clinical • CNS Disorders • Constipation • Depression • Developmental Disorders • Diabetes • Dyslipidemia • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Major Depressive Disorder • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder • MC4R

Prospective longitudinal multimodal study of adult attention deficit hyperactivity disorder in a transcultural cohort: clinical response, tolerability, and behavioral improvements (CINP 2026) - "Adults diagnosed with ADHD were recruited from multiple regions (Portugal, Brasil, Spain, France, Colombia, Venezuela, Russia), forming a transcultural cohort.Inclusion criteria required a confirmed ADHD diagnosis and consent to participate in longitudinal follow-up via teleconsultation in a private clinic.Initial assessments included the DIVA-5 Scale to quantify baseline symptom severity.Pharmacological interventions included lisdexamfetamine, methylphenidate extended-release (ER), methylphenidate immediate-release (IR), atomoxetine, clonidine and bupropion with individualized dosing and treatment switches as clinically indicated.Comorbidities were managed prior to ADHD-specific treatment. Stimulant therapy with lisdexamfetamine and methylphenidate was associated with superior symptomatic and behavioral outcomes compared to atomoxetine, which showed lower efficacy, particularly in Russian participants lacking access to stimulants.Presence of psychiatric comorbidities,..."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Personality Disorder • Psychiatry • Substance Abuse

Intranasal esketamine in treatment-resistant bipolar depression maintained on long-acting aripiprazole (CINP 2026) - " Case 1: A 30-year-old female with bipolar disorder was maintained on a monthly aripiprazole injection of 400 mg since June 2024 in combination with clomipramine 150mg, quetiapine 300mg, and lisdexamfetamine 30mg...Case 2: A 21-year-old female with bipolar disorder was maintained on a monthly aripiprazole injection 400 mg since February 2025 in combination with lithium 400 mg, lamotrigine 400mg, Zyprexa 10 mg, and bupropion 300mg...Case 3: A 31-year-old male with bipolar disorder was maintained on a monthly aripiprazole injection of 400 mg since May 2024in combination with desvenlafaxine 150mg...Case 4: A 38-year-old female with bipolar disorder was maintained on a monthly aripiprazole injection of 400 mg since July 2025 in combination with escitalopram 20 mg, Wellbutrin 300 mg, and lithium 400 mg. These cases demonstrated that there may be a role for adding intranasal esketamine in treatment-resistant bipolar depression in patients already maintained on monthly..."

Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Maintained Symptom Control Following a Shortage-Driven Switch to Immediate-Release Dextroamphetamine: A Case Report. (PubMed, Cureus) - "This case report describes a 30-year-old female who was unable to obtain lisdexamfetamine amid the shortage, found mixed amphetamine salts ineffective, but found success with immediate-release dextroamphetamine sulfate, a less frequently used amphetamine. This report serves to demonstrate that immediate-release dextroamphetamine sulfate may be a viable alternative stimulant to address the shortage; however, more research must be conducted to confirm these findings."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Isolated Agenesis of the Splenium of the Corpus Callosum Associated With Autism Spectrum Disorder: A Rare and Clinically Relevant Association. (PubMed, Cureus) - "The patient was treated with lisdexamfetamine and clonidine, showing improvement over time. Furthermore, it emphasizes the importance of individualized treatment as well as neuroimaging in atypical behavioral presentations. Further research is needed into the role of focal corpus callosum abnormalities in autism spectrum disorder (ASD)."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Developmental Disorders • Excessive Daytime Sleepiness • Genetic Disorders • Infectious Disease • Obstructive Sleep Apnea • Psychiatry • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Real-world evaluation of attention deficit hyperactivity disorder symptoms and side effects in patients prescribed serdexmethylphenidate/dexmethylphenidate or other stimulants. (PubMed, Front Pharmacol) - "This study compared the tolerability of SDX/d-MPH with other approved extended-release (ER) stimulant medications by evaluating patient-reported side effects in a real-world sample of patients with ADHD prescribed SDX/d-MPH, lisdexamfetamine (LDX), amphetamine ER (AMP), or methylphenidate ER (MPH). In this single-center retrospective analysis of patient surveys, patients with ADHD taking SDX/d-MPH reported reduced frequency of insomnia compared to AMP ER and LDX, and lower frequency of end-of-dose crash compared to AMP ER. This real-world tolerability analysis highlights the importance of considering side effects in ADHD treatment."

Adverse events • HEOR • Journal • Real-world evidence • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Insomnia • Psychiatry • Sleep Disorder

Stimulant Use is Associated With Reduced Semen Volume in Reproductive-Aged Men (AUA 2026) - "We excluded men with diagnoses of varicocele, cryptorchidism, genetic abnormality, diabetes mellitus, cancer, azoospermia, or prior use of testosterone therapy, clomiphene, anastrozole, hCG, 5-alpha reductase inhibitors, finasteride, or anti-neoplastic agents before semen analysis. Exposure was defined as an active outpatient prescription for methylphedinate, amphetamine, lisdexamfetamine, dextroamphetamine, or methamphetamine within 90 days prior to semen testing... Among reproductive-aged men with ADHD, recent stimulant use was associated with a modest but statistically significant reduction in semen volume, while other semen parameters remained unchanged. These findings suggest a potential effect of stimulants on ejaculatory physiology or accessory gland function rather than on sperm production. Importantly, preserved sperm quality and motility suggest that stimulant use during attempts at conception is unlikely to significantly impair fertility, though prospective..."

ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Diabetes • Metabolic Disorders

Attention-deficit/hyperactivity disorder stimulant use is associated with reduced semen volume in reproductive-age men: a multi-center analysis. (PubMed, Int J Impot Res) - "Exposure was defined as an active outpatient prescription for methylphenidate, amphetamine, lisdexamfetamine, dextroamphetamine, or methamphetamine within 90 days prior to semen testing. Among reproductive-age men with ADHD, recent stimulant use was associated with a modest decrease in semen volume, while other semen parameters remained unchanged. Importantly, preserved sperm quality suggests that stimulant use during attempts at conception is unlikely to significantly impair fertility."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

JORNAY PM® enhances ADHD symptom improvement vs other extended-release stimulants in women, without impacting depression or anxiety treatment response (APA 2026) - "Adults with ADHD prescribed any dose of lisdexamfetamine (LDX), amphetamine (AMP) ER, methylphenidate (MPH) ER, or JORNAY PM and ≥2 office visits were included. In adults with ADHD treated with ER stimulants, gender modified treatment response to JORNAY PM for ADHD symptoms measured by the ASSET, a validated symptom tracking scale. No differences between gender or treatments were found for PHQ-9 or GAD-7. The analyses are limited by small sample size and racial diversity of the included population."

Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Severe Homicidal Ideation and Violent Behavior Associated with Lisdexamfetamine (Vyvanse) in an Adolescent: A Case Report (APA 2026) - "Atomoxetine was titrated to 60 mg daily, and aripiprazole was increased to 10 mg nightly. Meta-analytic data further indicate that amphetamine-class stimulants, particularly at higher doses or in vulnerable patients, carry a greater risk of aggression and psychosis compared with methylphenidate. This case underscores the need for vigilance when prescribing stimulants in adolescents with complex psychiatric comorbidities."

Case report • Clinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Mood Disorders